OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Neuropathic Corneal Pain
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
    • NCP Expanded Access
  • Technology
    • Chemerin Receptor
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page

OKYO Pharma announces that the board of directors of the Company, acting on a recommendation of the Remuneration Committee has awarded options to directors and persons discharging managerial responsibility.

by admin | 15th March 2023 | News

OKYO Pharma Limited (“OKYO” or the “Company”) Grant of options –PDMR dealing London, March 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...

Recent Posts

  • OKYO Pharma to Present at the Bio International Convention
  • OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
  • FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
  • OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
  • OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023